Cite
Leal AS, Moerland JA, Zhang D, et al. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (Basel). 2021;13(19)doi: 10.3390/cancers13195004.
Leal, A. S., Moerland, J. A., Zhang, D., Carapellucci, S., Lockwood, B., Krieger-Burke, T., Aleiwi, B., Ellsworth, E., & Liby, K. T. (2021). The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers, 13(19), . https://doi.org/10.3390/cancers13195004
Leal, Ana S, et al. "The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer." Cancers vol. 13,19 (2021). doi: https://doi.org/10.3390/cancers13195004
Leal AS, Moerland JA, Zhang D, Carapellucci S, Lockwood B, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (Basel). 2021 Oct 06;13(19). doi: 10.3390/cancers13195004. PMID: 34638488; PMCID: PMC8508021.
Copy
Download .nbib